Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 10% and currently trading at 3.4 HKD, with a transaction volume of 11.32 million HKD, following the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Group 1: Product Development - The TONO-i device will be a crucial part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - TONO-i provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, facilitating immediate and continuous feedback on treatment efficacy, thereby improving patient compliance with glaucoma medication [1] Group 2: Distribution Agreement - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of developing diagnostic, therapeutic, and preventive medical devices for glaucoma [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]
港股异动 | 兆科眼科-B(06622)再涨超10% 公司向国家药监局取得供测量眼压的TONO-i的医疗器械注册证